DESCRIPTION

Halaven 0.44 mg is a anti-cancer drug manufactured under licence by NerPharma, marketed by Eisai Pharmaceuticals. Its generic name is Eribulin Mesylate. It is a drug approved by the US FDA for treatment of patients with metastatic breast cancer who have previously received two chemotherapeutic regimens for the treatment of metastatic disease.Previous therapy should have included an anthracycline and a taxane for either early or advanced breast cancer. It is in powder form in vial along with a solvent. Dosage is 0.88 mg/2ml. 

Manufacturer: Eisai Pharmaceuticals (Contract Manufacturer: NerPharma SRL, Italy)

ADDITIONAL INFORMATION

SIDE EFFECTS

Side Effects:

  1. The most common side effects reported in ?25% of patients receiving Halaven (eribulin mesylate) were low white blood cells; low red blood cells; weakness/tiredness; hair loss; numbness, tingling, or burning in the hands and feet; nausea; and constipation
  2. The most common serious side effects reported in patients receiving Halaven (Eribulin Mesylate) were neutropenia with or without a fever.

PACK SIZE

Mehan Biosciences is a WHO GDSP approved & licensed Pharmaceutical stockist/wholesaler/distributor/exporter/importer of Halaven 0.44 mg (2ml) based in India - To buy Halaven 0.44 mg (2ml) or know its cost price contact us here.

We supply & sell Halaven 0.44 mg (2ml) for Reference Listed Drugs, Government Tenders, Shortage Lists, Emergency Imports, Name Patient Drugs, Comparator Drug Studies, Un-licensed Importation, clinical trial samples & Bio-Similars.

Disclaimer

- We are not an online pharmacy selling drugs over the internet.
MBS

At MBS, we acknowledge the critical role that reliable sourcing and timely delivery play in the healthcare industry. MBS is your trusted partner in pharmaceutical supply chain management.

Company

Contact Us

Mehan Biosciences
Central Sales Depot
115, Vardhman Market, CSC
Ram Vihar, Delhi-110092, India
Phone - +91-011-41420448

Copyright 2024 | All Rights Reserved
Enquiry Form